Stejbach Mark 4
4 · Indivior Pharmaceuticals, Inc. · Filed Jan 28, 2026
Research Summary
AI-generated summary of this filing
Indivior Director Mark Stejbach Receives RSU Award of 3,722 Shares
What Happened
Mark Stejbach, a director of Indivior Pharmaceuticals, was granted 3,722 restricted stock units (RSUs) on January 26, 2026. The grant is reported at a $0.00 acquisition price, reflecting that these are compensatory RSUs rather than a market purchase. The Form 4 disclosing the grant was filed on January 28, 2026.
Key Details
- Transaction date: 2026-01-26 (reported on Form 4 dated 2026-01-28)
- Transaction type/code: Award/Grant (A) — 3,722 RSUs granted at $0.00 per unit
- Total reported acquisition value: $0 (grant of RSUs, not a cash purchase)
- Shares owned after transaction: not disclosed in the provided filing excerpt
- Footnote: Each RSU is a contingent right to one share; they vest on the day immediately preceding the Issuer's first annual stockholders' meeting after the grant date, subject to Stejbach’s continued service.
Context
RSU grants are a common form of director/executive compensation and do not represent an open-market purchase or sale. Because vesting is conditional on continued service, these RSUs don't transfer shares immediately and are not an immediate liquidity event. This filing is informational about compensation; it does not by itself indicate insider buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-26+3,722→ 20,569 total
Footnotes (1)
- [F1]Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.